Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2009

View Archived Issues

Clinical studies reveal efficacy of bepotastine in treating allergic conjunctivitis

Fourth quarter highlights at Merck KGaA

Novel substituted tetrahydronaphthalines claimed by sanofi-aventis

Novel b-Raf inhibitors claimed by Takeda

Agile signs clinical trial agreement for its progestin-only contraceptive patch AG-1000

FDA issues complete response letter to Dyax regarding BLA for DX-88 in HAE

Biogen Idec reports favorable interim results from phase IIa studies of BIIB-014 in PD

Infinity initiates phase II IPI-504 trial in HER2-positive breast cancer

Faron presents update on its lead compoumd Traumakine

FDA clears Curemark's IND for phase III clinical trial of CM-AT in autism

reMYND presents first-in-class drug candidates for Alzheimer's, Parkinson's disease

Oral MC-4 receptor antagonists developed by Santhera for cachexia

Novel compounds for the treatment of mood disorders presented by GlaxoSmithKline

Boehringer Ingelheim claims the discovery of novel arylsulfonamides with analgesic activity

Novel phosphodiesterase type 10 inhibitors claimed by Amgen

Portola Pharmaceuticals describes second-generation P2Y12 inhibitors

Dual specificity antibody displays in vitro and in vivo antiproliferative activity

Tadalafil improves benign prostatic hyperplasia symptoms regardless of erectile function status

Archemix initiates phase IIa ARC-1779 trial

EffRx signs expansion of licensing deal with Nycomed for EX-101

AstraZeneca to meet with FDA Psychopharmacologic Drugs Advisory Committee

Seattle Genetics receives FDA fast track for SGN-35 for Hodgkin's lymphoma

Arena reports pivotal phase III results for lorcaserin in obesity

PharmaMar and Taiho sign license agreement for antitumor drug Yondelis in Japan

Ixiaro vaccine receives FDA approval for Japanese encephalitis prevention

FDA approves Afinitor in patients with advanced kidney cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...